Leading BioSolutions Platform

Proforma Financial Results: H1 FY2020 Crore FY 20 FY19 Change Particulars H-1 PPA / H-1 H-1 % % * Crores % Reported Integration (Note 1) (Note 2) Total Revenue from operation 15,723 15,723 100% 14,471 100% 1,252 9% Variable Cost 9,468 414 9,054 8,156 898 11% Gross Margin 6,255 (414) 6,669 42% 6,315 44% 354 6% Fixed Overheads 3,470 3,470 3,440 30 1% EBITDA 2,785 (414) 3,199 20% 2,875 20% 324 11% Note : 1) Purchase Price Allocation effect and Integration cost are removed from H1 FY2020 2) Previous years numbers (including Arysta) have been regrouped for comparison purpose. UPL 48 48

View entire presentation